NM_014336.5(AIPL1):c.152A>G (p.Asp51Gly) is a missense variant predicted to replace the aspartic acid at position p.51 with glycine. This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.86, which is above the ClinGen LCA/eoRD VCEP threshold of ≥0.774 and predicts a damaging effect on AIPL1 protein function (PP3_Moderate). This variant has also been reported in 2 probands with early-onset severe retinal dystrophy who were compound heterozygous with the p.Gln141Ter variant confirmed in trans (2 points, PMID: 31630094), which was previously classified pathogenic by the ClinGen LCA/eoRD VCEP (2 total points, PM3_Strong). At least one proband harboring this variant exhibits a phenotype including diagnosis of LCA (0.5 pts) with onset at age 1 (1 pt) and has photophobia (1 pt), severely reduced electroretinogram responses from both rods (0.5 pts) and cones (1 pt), nystagmus (1 pt), decreased central visual acuity (1 pt), and has had gene panel testing with no additional likely cause found (2 pts). Together these are highly specific for AIPL1-related retinopathy (8 points, PMID: 31630094, PP4_Moderate). In summary, this variant meets the criteria to be classified as Likely Pathogenic for AIPL1-related retinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen LCA/eoRD VCEP: PM3_Strong, PP3_Moderate, PP4_Moderate, PM2_Supporting, (VCEP specifications version 1.0.0; date of approval 09/24/2025).